OncoMatch/Clinical Trials/NCT06513234
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Is NCT06513234 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Orelabrutinib and obinutuzumab for marginal zone lymphoma.
Treatment: Orelabrutinib and obinutuzumab — This is a prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab a in untreated marginal zone lymphoma. It is planned to recruit 45 patients. The primary endpoint is the complete remission rate at 12 months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (positive)
Histopathologically confirmed CD20-positive marginal zone lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L, platelets ≥75×10^9/L, hemoglobin ≥75g/L; if bone marrow involvement: ANC ≥1.0×10^9/L, platelets ≥50×10^9/L, hemoglobin ≥50g/L
Kidney function
serum creatinine ≤1.5x ULN
Liver function
Total bilirubin ≤1.5x ULN, AST or ALT ≤2x ULN
Cardiac function
LVEF ≥50%; no NYHA class II or above CHF, unstable angina, MI within 6 months, arrhythmias requiring treatment, primary cardiomyopathy, significant QTc prolongation (>470ms females, >450ms males), symptomatic or medication-requiring coronary artery disease, difficult-to-control hypertension
Major organ functions meet the following criteria: a) Complete blood count... b) Blood biochemistry... c) Coagulation function: INR ≤1.5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify